Gastrointestinal stromal tumours - imatinib: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Imatinib for the adjuvant treatment of gastrointestinal stromal tumours and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 9th July 2010.
‘No Comment’ responses received from:
- Department of Health
- Royal College of Nursing
- Royal College of Pathologists
- Welsh Assembly Government
Gastrointestinal stromal tumours - imatinib: final appraisal determination
Response to consultee and commentator comments on the Appraisal Consultation Document
Evidence Review Group - appraisal of the Novartis response to the ACD published March 2010
Novartis
Joint comment from British Society for Gastroenterology, GIST Support UK, JCCO, NCRI, Royal College of Physicians, RCR, Sarcoma UK
Dr David Cook, patient expert nominated by GIST Support UK
This page was last updated: 24 June 2010
